Prolong Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Prolong Pharmaceuticals's estimated annual revenue is currently $5.4M per year.(i)
  • Prolong Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Prolong Pharmaceuticals has 27 Employees.(i)
  • Prolong Pharmaceuticals grew their employee count by -7% last year.

Prolong Pharmaceuticals's People

NameTitleEmail/Phone
1
VP InnovationReveal Email/Phone
2
Materials ManagerReveal Email/Phone
3
Microbiology ManagerReveal Email/Phone
4
Maintenance Technician IVReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Prolong Pharmaceuticals?

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and significant mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases. - The company's lead product, SANGUINATEâ„¢, is focused on treating the comorbidities of sickle cell disease and hemorrhagic stroke - Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy - Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer ___________

keywords:N/A

N/A

Total Funding

27

Number of Employees

$5.4M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M27N/AN/A
#2
$4.6M270%N/A
#3
$5.8M32-3%N/A
#4
$3.7M327%N/A
#5
$5.3M330%$54M